Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Frederic Sweeney's Biography

Frederic Sweeney, Senior Director, T2 Biosystems

Dr. Frédéric Sweeney joined T2 Biosystems in February 2013 to lead the business development activities of the company. His career spans academic research, venture capital and private equity, as well as operations. Prior to joining T2 Biosystems, Fred was Vice-President of Business Development & Strategic Alliances for Tornado Spectral Systems (TSS), a commercial stage nanophotonics and spectroscopy technology company strongly driven by an OEM partnership business model. Having joined as an original founding member of the company, Fred managed all aspects of commercialization and go-to-market strategy for TSS’ product portfolio. He led a number of large partnership agreements with world-leading spectroscopy companies and several in/out-licensing deals. Fred also worked as part of the life sciences investment team at VenGrowth Private Equity Partners, one of Canada’s premier private equity and venture capital firms. His main responsibilities at VenGrowth were to provide operational support and coordinate follow-on investments for portfolio companies, as well as sourcing and performing due diligence on new investment opportunities for the firm. Fred also acted as an observer on the Board of numerous companies in the medical device, therapeutic, diagnostic and biomaterials space. Fred holds a Ph.D. in molecular and medical genetics from the University of Toronto as a Terry Fox Scholar of the National Cancer Institute of Canada. During his scientific training, he acquired a deep expertise in clinical diagnostics and cancer biology by using structural and molecular biology as well as small molecule biochemistry.

Frederic Sweeney Image

T2MR: Focused on Rapid & Sensitive Detection of Sepsis Pathogens Directly from Whole Blood Without Blood Culture

Tuesday, 28 October 2014 at 16:00

Add to Calendar ▼2014-10-28 16:00:002014-10-28 17:00:00Europe/LondonT2MR: Focused on Rapid and Sensitive Detection of Sepsis Pathogens Directly from Whole Blood Without Blood

Rapid diagnostic testing to narrow clinical trial populations and improve therapeutic efficacy has had limited benefit for antimicrobial therapies due to the low titer levels of infection and long diagnostic times required by the standard of care, blood culture. In order to truly make an impact in drug development as companion diagnostics, new technologies are required to deliver dramatically faster and more accurate results. The ideal diagnostics assays (1) would achieve clinically relevant limits of detection directly from patient samples, (2) would not rely on culture or enrichment and (3) would have very high positive and negative predictive values.  T2 Magnetic Resonance (T2MR®) technology has the potential to deliver a rapid, sensitive and simple diagnostic platform that can identify specific pathogens directly from an unpurified blood sample as fast as three hours.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion